Advances in the treatment of alpha1-antitrypsin deficiency

Jorge Lascano, Matthias A Salathe, Michael A Campos

Research output: Contribution to journalArticle

Abstract

Alpha1-antitrypsin deficiency (AATD) is an autosomal co-dominant condition characterised by low circulating levels of Alpha1-antitrypsin (AAT) and the accumulation of polymerised AAT molecules in the hepatocyte. Patients with this condition are susceptible to developing chronic lung and liver disease. Lung disease occurs in part from loss of neutrophil elastase inhibition and liver disease from a gain-of-toxic function and endoplasmic reticulum stress in hepatocytes. The pro-inflammatory nature of AAT polymers likely contributes to disease pathogenesis. New therapeutic efforts are being developed targeting specific pathophysiology mechanisms of the disease. These include increasing circulating AAT levels above the current therapeutic target with higher doses of intravenous AAT or by direct administration to the lung via the inhaled route. Other efforts include gene therapy and development of strategies to decrease the intracellular accumulation of AAT polymers by enhancing cellular degradation mechanisms, using chemical chaperones to target protein misfolding and designing molecules that can act as blockers of AAT polymerisation.

Original languageEnglish
Pages (from-to)122-126
Number of pages5
JournalEuropean Respiratory Disease
Volume7
Issue number2
StatePublished - Sep 1 2011

Fingerprint

Lung Diseases
Liver Diseases
Hepatocytes
Polymers
Leukocyte Elastase
Endoplasmic Reticulum Stress
Poisons
Polymerization
Genetic Therapy
Chronic Disease
Lung
Therapeutics
Proteins

Keywords

  • Alpha1-antitrypsin
  • Alpha1-antitrypsin deficiency
  • Treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Advances in the treatment of alpha1-antitrypsin deficiency. / Lascano, Jorge; Salathe, Matthias A; Campos, Michael A.

In: European Respiratory Disease, Vol. 7, No. 2, 01.09.2011, p. 122-126.

Research output: Contribution to journalArticle

Lascano, Jorge ; Salathe, Matthias A ; Campos, Michael A. / Advances in the treatment of alpha1-antitrypsin deficiency. In: European Respiratory Disease. 2011 ; Vol. 7, No. 2. pp. 122-126.
@article{7474d57e1ff347c690f9924da98117f2,
title = "Advances in the treatment of alpha1-antitrypsin deficiency",
abstract = "Alpha1-antitrypsin deficiency (AATD) is an autosomal co-dominant condition characterised by low circulating levels of Alpha1-antitrypsin (AAT) and the accumulation of polymerised AAT molecules in the hepatocyte. Patients with this condition are susceptible to developing chronic lung and liver disease. Lung disease occurs in part from loss of neutrophil elastase inhibition and liver disease from a gain-of-toxic function and endoplasmic reticulum stress in hepatocytes. The pro-inflammatory nature of AAT polymers likely contributes to disease pathogenesis. New therapeutic efforts are being developed targeting specific pathophysiology mechanisms of the disease. These include increasing circulating AAT levels above the current therapeutic target with higher doses of intravenous AAT or by direct administration to the lung via the inhaled route. Other efforts include gene therapy and development of strategies to decrease the intracellular accumulation of AAT polymers by enhancing cellular degradation mechanisms, using chemical chaperones to target protein misfolding and designing molecules that can act as blockers of AAT polymerisation.",
keywords = "Alpha1-antitrypsin, Alpha1-antitrypsin deficiency, Treatment",
author = "Jorge Lascano and Salathe, {Matthias A} and Campos, {Michael A}",
year = "2011",
month = "9",
day = "1",
language = "English",
volume = "7",
pages = "122--126",
journal = "European Respiratory Disease",
issn = "1754-5552",
publisher = "Touch Briefings",
number = "2",

}

TY - JOUR

T1 - Advances in the treatment of alpha1-antitrypsin deficiency

AU - Lascano, Jorge

AU - Salathe, Matthias A

AU - Campos, Michael A

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Alpha1-antitrypsin deficiency (AATD) is an autosomal co-dominant condition characterised by low circulating levels of Alpha1-antitrypsin (AAT) and the accumulation of polymerised AAT molecules in the hepatocyte. Patients with this condition are susceptible to developing chronic lung and liver disease. Lung disease occurs in part from loss of neutrophil elastase inhibition and liver disease from a gain-of-toxic function and endoplasmic reticulum stress in hepatocytes. The pro-inflammatory nature of AAT polymers likely contributes to disease pathogenesis. New therapeutic efforts are being developed targeting specific pathophysiology mechanisms of the disease. These include increasing circulating AAT levels above the current therapeutic target with higher doses of intravenous AAT or by direct administration to the lung via the inhaled route. Other efforts include gene therapy and development of strategies to decrease the intracellular accumulation of AAT polymers by enhancing cellular degradation mechanisms, using chemical chaperones to target protein misfolding and designing molecules that can act as blockers of AAT polymerisation.

AB - Alpha1-antitrypsin deficiency (AATD) is an autosomal co-dominant condition characterised by low circulating levels of Alpha1-antitrypsin (AAT) and the accumulation of polymerised AAT molecules in the hepatocyte. Patients with this condition are susceptible to developing chronic lung and liver disease. Lung disease occurs in part from loss of neutrophil elastase inhibition and liver disease from a gain-of-toxic function and endoplasmic reticulum stress in hepatocytes. The pro-inflammatory nature of AAT polymers likely contributes to disease pathogenesis. New therapeutic efforts are being developed targeting specific pathophysiology mechanisms of the disease. These include increasing circulating AAT levels above the current therapeutic target with higher doses of intravenous AAT or by direct administration to the lung via the inhaled route. Other efforts include gene therapy and development of strategies to decrease the intracellular accumulation of AAT polymers by enhancing cellular degradation mechanisms, using chemical chaperones to target protein misfolding and designing molecules that can act as blockers of AAT polymerisation.

KW - Alpha1-antitrypsin

KW - Alpha1-antitrypsin deficiency

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84870154183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870154183&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 122

EP - 126

JO - European Respiratory Disease

JF - European Respiratory Disease

SN - 1754-5552

IS - 2

ER -